The discovery of epidermal growth factor receptor (EGFR) mutations and the advent of EGFR-tyrosine kinase inhibitors (TKIs) have dramatically shifted the therapeutic landscape of non-small cell lung cancer (NSCLC) from traditional chemotherapy to molecular targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.